Company Encyclopedia
View More
name
Genmab A/S
GMAB.US
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease.
1.946 T
GMAB.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking14/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE29.41%A
    • Profit Margin41.17%A
    • Gross Margin94.32%A
  • Growth ScoreA
    • Revenue YoY32.26%A
    • Net Profit YoY129.81%A
    • Total Assets YoY18.25%A
    • Net Assets YoY20.34%A
  • Cash ScoreB
    • Cash Flow Margin242.89%C
    • OCF YoY32.26%A
  • Operating ScoreB
    • Turnover0.58B
  • Debt ScoreA
    • Gearing Ratio18.09%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    How stock of the day Genmab is leveraging an $8 billion deal to stoke its next chapter

    Genmab stock, Thursday's IBD Stock Of The Day, is just below an early entry in a cup case after announcing an $8 billion deal to buy Merus.

    MSN·
    US
    GMAB
    +1.07%
    MSN·
    US
    GMAB
    +1.07%

    Genmab Closes $2.5 Billion Notes Offering to Fund Merus Acquisition

    Genmab A/S has closed a $2.5 billion notes offering, raising $1.5 billion through 6.250% senior secured notes due 2032 and $1.0 billion through 7.250% senior unsecured notes due 2033. The proceeds will finance the acquisition of Merus N.V. and cover related expenses.

    Reuters·
    US
    GMAB
    +1.07%
    Reuters·
    US
    GMAB
    +1.07%

    Genmab, Pfizer's Cervical Cancer Drug Gets UK Regulatory Nod

    Genmab, Pfizer's Cervical Cancer Drug Gets UK Regulatory Nod

    marketscreener·
    US
    GMAB
    +1.07%
    US
    PFE
    +0.51%
    marketscreener·
    US
    GMAB
    +1.07%
    US
    PFE
    +0.51%

    Genmab A/S Updates Articles of Association for Financial Flexibility

    Genmab A/S announced updates to its Articles of Association, authorizing the Board to increase share capital and issue warrants and convertible debt instruments. This aims to provide financial flexibility and support growth strategy. The latest analyst rating on GMAB stock is a Buy with a $45.00 price target. Genmab is rated as Outperform by TipRanks' AI Analyst, Spark, due to strong financial performance and strategic initiatives.

    Tip Ranks·
    US
    GMAB
    +1.07%
    Tip Ranks·
    US
    GMAB
    +1.07%

    Genmab A/S (NASDAQ:GMAB) Upgraded at Wall Street Zen

    Wall Street Zen upgraded Genmab A/S (NASDAQ:GMAB) from a "hold" to a "buy" rating. Other analysts, including Guggenheim and HC Wainwright, also issued buy ratings, while Zacks Research downgraded it to "hold." The stock has a consensus rating of "Moderate Buy" with an average target price of $39.75. Genmab A/S reported strong quarterly earnings, surpassing estimates, and has seen significant institutional investment.

    Market Beat·
    US
    GMAB
    +1.07%
    Market Beat·
    US
    GMAB
    +1.07%
    © 2025 Longbridge｜Disclaimer